A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

PURPOSE: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Leuk Res
Main Authors: Sweet, Kendra, Hazlehurst, Lori, Sahakian, Eva, Powers, John, Nodzon, Lisa, Kayali, Fadi, Hyland, Kelly, Nelson, Ashley, Pinilla-Ibarz, Javier
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787269/
https://ncbi.nlm.nih.gov/pubmed/30340199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.10.002
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki